Skip to main content
. Author manuscript; available in PMC: 2023 Jun 21.
Published in final edited form as: Drug Metab Rev. 2022 Aug 5;54(3):246–281. doi: 10.1080/03602532.2022.2097254

Figure 1.

Figure 1.

(A) AO substrates demonstrating different degrees of inactivation of the wild-type and L438V enzymes, presumably due to different substrate turnover rates resulting in different rates of ROS production. Arrows indicate site of AO oxidation. (B) AO mechanism of substrate oxidation and catalytic cycle. The authors propose that ROS produced as a consequence of substrate oxidation inactivates the enzyme via desulfuration of the molybedenum cofactor.